A detailed history of Geode Capital Management, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,089,304 shares of PCRX stock, worth $16.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,089,304
Previous 1,036,681 5.08%
Holding current value
$16.4 Million
Previous $30.3 Million 2.88%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$25.5 - $31.51 $1.34 Million - $1.66 Million
52,623 Added 5.08%
1,089,304 $31.2 Million
Q1 2024

May 13, 2024

BUY
$27.7 - $35.48 $915,872 - $1.17 Million
33,064 Added 3.29%
1,036,681 $30.3 Million
Q4 2023

Feb 13, 2024

BUY
$26.32 - $34.31 $1.24 Million - $1.62 Million
47,240 Added 4.94%
1,003,617 $33.9 Million
Q3 2023

Nov 13, 2023

BUY
$30.68 - $40.09 $1.13 Million - $1.47 Million
36,776 Added 4.0%
956,377 $29.3 Million
Q2 2023

Aug 11, 2023

BUY
$36.12 - $47.5 $1.33 Million - $1.75 Million
36,817 Added 4.17%
919,601 $36.8 Million
Q1 2023

May 15, 2023

BUY
$35.53 - $43.38 $1.3 Million - $1.59 Million
36,621 Added 4.33%
882,784 $36 Million
Q4 2022

Feb 13, 2023

BUY
$38.19 - $57.45 $1.02 Million - $1.54 Million
26,833 Added 3.27%
846,163 $32.7 Million
Q3 2022

Nov 14, 2022

BUY
$51.24 - $58.89 $1.14 Million - $1.31 Million
22,177 Added 2.78%
819,330 $43.6 Million
Q2 2022

Aug 12, 2022

BUY
$51.49 - $81.64 $326,498 - $517,679
6,341 Added 0.8%
797,153 $46.5 Million
Q1 2022

May 13, 2022

SELL
$60.03 - $76.49 $2.78 Million - $3.54 Million
-46,321 Reduced 5.53%
790,812 $60.4 Million
Q4 2021

Feb 11, 2022

BUY
$47.97 - $62.21 $406,977 - $527,789
8,484 Added 1.02%
837,133 $50.4 Million
Q3 2021

Nov 12, 2021

BUY
$54.64 - $61.3 $66,770 - $74,908
1,222 Added 0.15%
828,649 $46.4 Million
Q2 2021

Aug 13, 2021

BUY
$59.18 - $69.99 $2.03 Million - $2.41 Million
34,365 Added 4.33%
827,427 $50.2 Million
Q1 2021

May 12, 2021

BUY
$59.31 - $78.82 $2.98 Million - $3.96 Million
50,220 Added 6.76%
793,062 $55.6 Million
Q4 2020

Feb 12, 2021

BUY
$50.47 - $66.26 $2.63 Million - $3.45 Million
52,106 Added 7.54%
742,842 $44.5 Million
Q3 2020

Nov 13, 2020

SELL
$51.97 - $63.0 $718,537 - $871,038
-13,826 Reduced 1.96%
690,736 $41.5 Million
Q2 2020

Aug 13, 2020

BUY
$30.8 - $52.47 $1 Million - $1.7 Million
32,479 Added 4.83%
704,562 $37 Million
Q1 2020

May 14, 2020

BUY
$28.4 - $50.7 $916,297 - $1.64 Million
32,264 Added 5.04%
672,083 $22.5 Million
Q4 2019

Feb 13, 2020

BUY
$36.31 - $46.83 $733,570 - $946,106
20,203 Added 3.26%
639,819 $29 Million
Q3 2019

Nov 12, 2019

BUY
$35.66 - $44.99 $242,345 - $305,752
6,796 Added 1.11%
619,616 $23.6 Million
Q2 2019

Aug 14, 2019

BUY
$36.57 - $47.97 $2.34 Million - $3.07 Million
63,996 Added 11.66%
612,820 $26.7 Million
Q1 2019

May 14, 2019

BUY
$36.47 - $42.17 $1.17 Million - $1.35 Million
32,050 Added 6.2%
548,824 $20.9 Million
Q4 2018

Feb 13, 2019

BUY
$41.31 - $52.16 $1.47 Million - $1.86 Million
35,635 Added 7.41%
516,774 $22.2 Million
Q3 2018

Nov 13, 2018

BUY
$32.85 - $52.0 $867,469 - $1.37 Million
26,407 Added 5.81%
481,139 $23.6 Million
Q2 2018

Aug 14, 2018

BUY
$27.5 - $39.8 $1.03 Million - $1.49 Million
37,333 Added 8.94%
454,732 $14.6 Million
Q1 2018

May 15, 2018

SELL
$29.98 - $46.35 $115,063 - $177,891
-3,838 Reduced 0.91%
417,399 $13 Million
Q4 2017

Feb 13, 2018

BUY
$31.85 - $46.95 $145,299 - $214,185
4,562 Added 1.09%
421,237 $19.2 Million
Q3 2017

Nov 14, 2017

BUY
$35.7 - $39.5 $500,692 - $553,987
14,025 Added 3.48%
416,675 $15.6 Million
Q2 2017

Aug 14, 2017

BUY
N/A
402,650
402,650 $19.2 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $690M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.